GPX1 and inflammatory bowel disease: Genetic polymorphisms in SOD2 have also been referred [17] as a potential mechanism interfering in the pharmaco-response of cells exposed to methotrexate (MTX), an immunomodulator commonly prescribed to IBD patients, and an interdependent mechanism of action between SOD2 and GPX1 has been suggested, indicating that these genes could also have an important role for therapeutic management.